Bonesupport Holding ABBOEUF 77 Return-on-Tangible-Equity is 24.01% as of Mar. 2026. GuruFocus rates BOEUF with a GF Score™ of 77/100 and a GF Value™ of $42.62 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Bonesupport Holding AB ranks better than 84.83% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Bonesupport Holding AB's annualized net income for the quarter that ended in Mar. 2026 was $22.9 Mil. Bonesupport Holding AB's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $95.5 Mil. Therefore, Bonesupport Holding AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 24.01%.
The historical rank and industry rank for Bonesupport Holding AB's Return-on-Tangible-Equity or its related term are showing as below:
BOEUF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -487.25 Med: -33.23 Max: 61.76
Current: 22.54
During the past 12 years, Bonesupport Holding AB's highest Return-on-Tangible-Equity was 61.76%. The lowest was -487.25%. And the median was -33.23%.
BOEUF's Return-on-Tangible-Equity is ranked better than 84.83% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.08
vs BOEUF: 22.54
Bonesupport Holding AB (OTCPK:BOEUF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Bonesupport Holding AB Return-on-Tangible-Equity Related Terms
Bonesupport Holding AB Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Bonesupport Holding AB's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bonesupport Holding AB Return-on-Tangible-Equity Chart
BOEUF vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Bonesupport Holding AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bonesupport Holding AB Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bonesupport Holding AB's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Bonesupport Holding AB's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 24.01% mean?
Bonesupport Holding AB (BOEUF) has a Return-on-Tangible-Equity of 24.01% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bonesupport Holding AB and its competitors. According to the industry distribution chart, Bonesupport Holding AB ranks #115 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 15.2%.
Is Bonesupport Holding AB's Return-on-Tangible-Equity too high?
Bonesupport Holding AB's current Return-on-Tangible-Equity is 24.01%. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.08. Bonesupport Holding AB's value of 24.01% is 488.5% above this industry median. Based on the distribution chart, Bonesupport Holding AB ranks #115 out of 758 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bonesupport Holding AB has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bonesupport Holding AB's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bonesupport Holding AB ranks #115 out of 758 companies for Return-on-Tangible-Equity. This places Bonesupport Holding AB in the top 15% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.08. Bonesupport Holding AB's value of 24.01% is 488.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bonesupport Holding AB's current Return-on-Tangible-Equity of 24.01% is 488.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bonesupport Holding AB and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bonesupport Holding AB's current Return-on-Tangible-Equity is 24.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonesupport Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Bonesupport Holding AB (BOEUF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.62, compared to a current price of $21.40 — trading 49.8% below its estimated fair value. The current Return-on-Tangible-Equity is 24.01% and 488.5% above the Medical Devices & Instruments industry median of 4.08. Bonesupport Holding AB's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Bonesupport Holding AB (BOEUF), the current Return-on-Tangible-Equity is 24.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bonesupport Holding AB (BOEUF) Overvalued in 2026?
Based on GuruFocus' analysis, Bonesupport Holding AB stock appears to be undervalued.
The current stock price of $21.40 is trading 49.8% below its estimated GF Value™ of $42.62.
GuruFocus considers Bonesupport Holding AB to be Significantly Undervalued.
Key valuation signals for BOEUF:
Return-on-Tangible-Equity: 24.01%
GF Value™: $42.62 vs. price of $21.40 (49.8% below fair value)
Industry Position: 488.5% above the Medical Devices & Instruments median (#115 of 758)
No single metric tells the full story. See the BOEUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bonesupport Holding AB is a fast-growing ortho-biologics company that focuses on the treatment of bone disorders. The Company develops and commercializes injectable bio-ceramic bone graft substitutes based on its CERAMENT platform, which remodels to bone and can release pharmaceuticals to promote healing. The products of the company focus on trauma, revision arthroplasty (replacement of joint prostheses), chronic osteomyelitis (bone infection), and foot and ankle surgery. The Group manages and monitors operations in two operating segments: United States and Europe & Rest of the World (EUROW).
77GF Score
Get the complete analysis for BOEUF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOEUF has been successfully added to your 
